home / stock / artl / artl news

ARTL News and Press, Artelo Biosciences Inc. From 08/16/22

Stock Information
Company Name: Artelo Biosciences Inc.
Stock Symbol: ARTL
Market: OTC
Website: artelobio.com
Menu
ARTL ARTL Quote ARTL Short ARTL News ARTL Articles ARTL Message Board
Get ARTL Alerts

News, Short Squeeze, Breakout and More Instantly...
ARTL - Artelo, Ventyx top healthcare gainers; Albireo, Sema4 lead losers' pack

Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...
ARTL - Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Nano-cap stock Artelo Biosciences ( NASDAQ: ARTL ) added ~21% in the morning hours Tuesday after the clinical-stage pharma announced the recent publication of pre-clinical data supporting the potential of its FABP inhibitor therapeutic platform in anxiety-related disorders...

ARTL - Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, t...

ARTL - DNA, KIND and ARTL are among pre market gainers

AMTD IDEA ( AMTD ) +38% Group to Inject US$500 Million Worth of Global Portfolio of Premium Real Estate Assets Located in Major Cities into AMTD Digital Inc. Ginkgo Bioworks Holdings ( DNA ) +22% . Zymergen ( ZY ) +20% Q2 earnings release . Gree...
ARTL - Artelo Biosciences GAAP EPS of -$0.87

Artelo Biosciences press release ( NASDAQ: ARTL ): Q2 GAAP EPS of -$0.87. As of June 30, 2022, the Company had approximately $21.3 million in cash and investments, compared to $25.6 million as of December 31, 2021. Shares -5.76% PM. For further details see: ...

ARTL - Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 20...

ARTL - Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, toda...
ARTL - Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, a...

ARTL - Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland

SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, a...

ARTL - Artelo Biosciences to Present at the LD Micro Invitational XII on June 7th

SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL) , a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the ...
Previous 10 Next 10